Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.
24
The U.S. Food and Drug Administration today cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom.
The uptake of risk-reducing surgery in women at increased risk of breast and ovarian cancer is highly variable between countries and centers within countries. We have investigated the rate, timing, and age of uptake of surgery in the northwest of U.K. to report the results after up to 7 years in a Regional Genetics center, scientists in Manchester, the United Kingdom report.
The U.S. Food and Drug Administration (FDA) today cleared the OVA1 Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass.
The ThinPrep Imaging System (TIS) was implemented at Brooke Army Medical Center (BAMC) in February 2006 and has been a crucial part of the ability of the Department of Pathology and Laboratory Services ability to improve efficiency and turnaround times for Papanicolaou (Pap) test reporting.
According to a study from the United States, The vast majority of cases of ovarian cancer are diagnosed at stage III or IV, and five-year survival rates after diagnosis at these stages are 71% and 31%, respectively. Although a consensus among researchers on the signs and symptoms of ovarian cancer has evolved over time, whether women themselves know them isn't dear.
23
Mary Foust knew something was wrong eight years ago. She was feeling bloated, fatigued and had pain in her abdomen. They're all things that women have, so it's real easy to ignore them, Foust said.
21
The tale the three women told scared the young medical students. The women spoke of a stealth disease that stalked them while doctors missed it. The women knew something was wrong. Yet no one found the disease until it had reached an advanced stage, until some women had so much abdominal swelling that it looked as if they were pregnant.
17
OSI Pharmaceuticals, Inc. announced the initiation of two clinical trials with OSI-906, the Company's potential first-in- class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).
Merck & Co., Inc. announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.
Central nervous system involvement is a rare finding in the management of epithelial ovarian cancer with an incidence between 1-2%. A sharp rise in the incidence has been widely and repeatedly proclaimed for nearly two decades now, but has to be treated with scepticism after a careful review of the current literature, researchers in Berlin, Germany report.
We care about your feedback. Let us know how we can improve your CancerCompass experience.